Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma

This trial assessed progression-free survival as a primary endpoint in 113 patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors who were treated with cixutumumab.

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. 

Study results demonstrated that 57 percent of patients with a soft tissue sarcoma known as adipocytic sarcoma (a rare tumor that develops from fat cells) experienced stable disease. 

Cixutumumab is a monoclonal antibody that targets the insulin-like growth factor-1 (IGF-1) receptor.  The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to therapy.

This trial assessed progression-free survival as a primary endpoint in 113 patients with advanced or